Steve Coats

Steve Coats has been Chief Development Officer of ImmunOs since December 2021. He has over 25 years of experience as a biopharmaceutical research and development executive, leading non-clinical, clinical and technology teams to develop innovative biologic-based therapies using multiple technology platforms in a variety of therapeutic areas. Steve spent over 15 years at AstraZeneca/MedImmune, most recently serving as VP of R&D, where he led global project teams developing novel biologic therapies through IND/CTA filings and proof of concept phase 2 clinical trials. Prior to AstraZeneca, Steve was a research director at Amgen where he led research and discovery teams for both small molecules as well as biologic therapies. Steve completed post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle with a focus on signal transduction and the cell cycle. He holds a Ph.D. in molecular and cell biology from Vanderbilt University and a B.A. from the University of New Hampshire.